Eli Lilly and Company $LLY Stock Position Increased by Berger Financial Group Inc

Berger Financial Group Inc raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,712 shares of the company’s stock after purchasing an additional 169 shares during the period. Berger Financial Group Inc’s holdings in Eli Lilly and Company were worth $5,233,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its holdings in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at about $4,613,912,000. Vanguard Group Inc. grew its position in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Cohen Investment Advisors LLC increased its stake in Eli Lilly and Company by 7,975.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after buying an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after buying an additional 765,010 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock worth $2,894,841 in the last quarter. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on LLY. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research note on Sunday, August 17th. Berenberg Bank reiterated a “hold” rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Saturday, September 27th. Finally, HSBC boosted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $938.94.

Eli Lilly and Company Trading Up 2.5%

NYSE:LLY opened at $840.46 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The firm has a market capitalization of $795.47 billion, a price-to-earnings ratio of 54.93, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The stock has a fifty day simple moving average of $734.60 and a 200 day simple moving average of $765.98.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. The business’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.